Regains Compliance with Rule 5550(b)(2)
EDINBURGH, Scotland, July 31,
2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC
BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage
biotechnology company developing platform allogeneic gamma-delta T
cell therapies for cancer, announced that the Company has regained
compliance with the Nasdaq Stock Market Listing Rule 5550(b)
which will maintain the listing of the Company's American
depositary shares on the Nasdaq Global Select Market.
As previously reported on January 19,
2019, the Company received a letter from the listing
qualifications staff of the Nasdaq Stock Market, LLC ("Nasdaq")
indicating that the Company has not regained compliance with the
minimum Market Value of Listed Securities ("MVLS")
of $35,000,000 required for continued listing on The
Nasdaq Capital Market or the alternative criteria , as set forth in
Nasdaq Listing Rule 5550(b) (the "MVLS Requirement").
Subsequently, the Company submitted to Nasdaq a plan to regain
compliance with Nasdaq listing rules. After reviewing the plan of
the Company to regain compliance, On July
27, 2023, we received a letter from Nasdaq notifying the
Company that the Panel has concluded we have regained compliance
with the shareholder equity concerns as mentioned previously. The
Company will be subject to a Mandatory Panel Monitor for a period
of one year from July 27, 2023.
For more information, please view the 6K filing here:
https://www.sec.gov/Archives/edgar/data/1872812/000149315223025993/form6-k.htm
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
gamma-delta T cell therapies for the treatment of cancer with human
efficacy data in acute myeloid leukemia. Gamma-delta T cells are
naturally occurring immune cells that embody properties of both the
innate and adaptive immune systems and can intrinsically
differentiate between healthy and diseased tissue. TC BioPharm uses
an allogeneic approach in both unmodified and CAR modified
gamma-delta T cells to effectively identify, target and eradicate
both liquid and solid tumors in cancer.
TC BioPharm is the leader in developing gamma-delta T cell
therapies, and the first company to conduct phase II/pivotal
clinical studies in oncology. The Company is conducting two
investigator-initiated clinical trials for its unmodified
gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of
acute myeloid leukemia using the Company's proprietary allogeneic
CryoTC technology to provide frozen product to clinics worldwide.
TC BioPharm also maintains a robust pipeline for future indications
in solid tumors as well as a significant IP/patent portfolio in the
use of CARs with gamma-delta T cells and owns our manufacturing
facility to maintain cost and product quality controls.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tc-biopharm-maintains-nasdaq-listing-301889218.html
SOURCE TC BioPharm